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Objective: To determine the prevalence and risk factors associated with drug resistance
tuberculosis (TB) at facility-base level in Tanga, Tanzania.
Methods: A total of 79 Mycobacterium tuberculosis (MTB) isolates included in the
study were collected from among 372 (312 new and 60 previously treated) TB suspects
self-referred to four TB clinics during a prospective study conducted from November
2012 to January 2013. Culture and drug susceptibility test of the isolates was performed
at the institute of medical microbiology and epidemiology of infectious diseases, Uni-
versity hospital, Leipzig, Germany. Data on the patient's characteristics were obtained
from structured questionnaire administered to the patients who gave informed verbal
consent. Unadjusted bivariate logistic regression analysis was performed to assess the risk
factors for drug resistant-TB. The signiﬁcance level was determined at P < 0.05.
Results: The overall proportions of any drug resistance and MDR-TB were 12.7% and
6.3% respectively. The prevalence of any drug resistance and MDR-TB among new cases
were 11.4% and 4.3% respectively, whereas among previously treated cases was 22.2%
respectively. Previously treated patients were more likely to develop anti-TB drug
resistance. There was no association between anti-TB drug resistances (including MDR-
TB) with the risk factors analysed.
Conclusions: High proportions of anti-TB drug resistance among new and previously
treated cases observed in this study suggest that, additional efforts still need to be done in
identifying individual cases at facility-base level for improved TB control programmes
and drug resistance survey should continuously be monitored in the country.1. Introduction
Tuberculosis (TB) continues to be a major health challenge
globally despite the efforts to combat the disease. Increased drug
resistant strains in many parts of the world has worsen the sit-
uation [1]. Escalating human immunodeﬁciency virus (HIV)
infection, increased prevalence of nontuberculousmycobacteria (NTM), poverty, and inadequacy public health
infrastructure have also contributed greatly in worsening the
situation [2].
During the last two decades, the World Health Organization
and the International Union Against Tuberculosis and Lung
Disease set up a global project to monitor the development of
drug-resistant tuberculosis (DR-TB). Since that time approxi-
mately 60% of all countries in the world have implemented
surveillance activities [3].
HIV epidemic and the emergence of drug resistant TB
threaten the efforts to reduce the global burden of TB by 2015
that aims at ensuring that all TB patients beneﬁt from universal
access to high-quality diagnosis and patient-centred treatment
[4]. Treatment of multi-drug resistant-TB (MDR-TB) isen access article under the CC BY-NC-ND
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toxic drugs compared to drug susceptible TB [5,6]. Incorrect drug
regimes, non-adherence to treatment, transmission in congregate
settings, substandard drug quality, as well as erratic drug supply
are key risk factors for drug resistance development [7,8]. Several
studies have reported unacceptably high mortality rates among
HIV-infected patients with MDR-TB [9,10].
Principally, drug resistance data are obtained through
continuous surveillance by routine testing of all TB patients.
However, in resource-poor settings like Tanzania, periodic drug
resistance surveys (DRS) based on random, representative drug
susceptibility testing (DST) among previously untreated smear-
positive cases are seldom performed. Laboratories performing
culture and DST are scarce and very often overburdened with
divergent tasks for the TB control programme. Consequently,
only phenotypic DST has been customarily performed;
frequently faced with notable logistics and operational chal-
lenges [11], and therefore impeding regular DRS and precise
surveillance. Generally, DST of Mycobacterium tuberculosis
(M. tuberculosis) (MTB) demands the presence of bio-safety
laboratories, which are rarely found outside reference centres
in many resource-poor settings. Moreover, rapid transport of
sputum from remote areas of the country to the reference labo-
ratory is required to minimize losses due to contamination or
growth failure. Poor infrastructure and unsustainable logistics in
these settings humper this.
Tanzania is among the 22 high TB burden countries, with an
estimated incidence (all forms) in 2007 and 2012 of 297 and 295
per 100 000 population respectively [12,13]. Available data on the
prevalence of DR-TB and MDR-TB in Tanzania are still low
owing to improved case management. Although the levels of
anti-TB drug resistance in the country are still low, the need for
continuous monitoring has always been emphasized [11,14]. The
most effective strategies for limiting further spread of drug-
resistant TB include rapid detection of drug resistance fol-
lowed by prompt and effective therapy of each case. Routine
surveillance linked to patient care, represents the best approach
to monitor drug resistance [3].
Limited anti-TB drug resistance surveys have been con-
ducted in Tanzania, the last one being in 2007 as part of national
representative sample of TB patients [11]. Since that time, no
survey has been conducted outside the national survey. The
present study aimed at assessing the magnitude of anti-TB
drug resistance and associated risks among newly, and previ-
ously treated pulmonary TB patients at facility-base level in
Tanga, Tanzania.
2. Materials and methods
2.1. Study design, area and study population
A total of 79 M. tuberculosis isolates collected from among
372 new and previously treated TB patients during a prospective
study conducted in Tanga, Tanzania from November 2012 to
January 2013 were eligible for this study. All patients with
clinical signs and symptoms suggestive of TB self-referred to
four TB clinics were eligible for the study. The clinics included
Makorora and Ngamiani health centres, Bombo Regional
referral hospital and Muheza designated District hospital. De-
mographic information and data were collected only after pro-
vision of informed consent. A careful cross examination of
patient history for previous anti-TB treatment using a structuredquestionnaire was used to classify patients as ‘new’ or ‘repeat’
TB cases. A patient was considered as ‘new case’ if had not
received anti-TB treatment for a period >1 month and was
considered ‘repeat’ if had received anti-TB drugs in a period less
or equal to 1 month. No restrictions on inclusion criteria
regarding clinical symptoms and age of the patients.
2.2. Sputum and data collection
Demographic data was obtained by using structured ques-
tionnaire administered to the patients attending four TB clinics
who provided informed verbal consent to the study. Two sputum
samples (one spot during the initial visit to the clinic and one
early morning) were collected into small autoclavable wide
mouth glass bottles. The specimens were examined by direct
smear microscopy at the respective clinics using either Ziehl
Neelsen-stain (Makorora and Ngamian health centres) or ﬂuo-
rescence stain (Bombo referral hospital and MDHH). Diagnosis
of smear-positive TB was performed based on the national
tuberculosis and leprosy programme guidelines [15]. All morning
sputum samples were kept at −20 C at the respective clinics. No
preservative was added until shipped to the Institute of Medical
Microbiology and Epidemiology of Infectious Diseases,
University hospital, Leipzig, Germany for culture and
molecular analysis. HIV status of the patients was determined
by rapid HIV screening method at the treatment and care
centres of the respective clinics.
2.3. Sputum culture and identiﬁcation of mycobacterial
isolates
Sputum specimens were digested and decontaminated using
N-acetyl-L-cysteine-sodium hydroxide method [16] and were re-
examined for the presence of acid-fast bacilli by ﬂuorescence
stain in Leipzig. The isolates were cultured in BacT/Alert® 3D
liquid culture system (bioMe'rieux) and on Lo¨weinstein- Jensen
andGottsacker slants (Artelt-ENCLITGmbH,Wyhra, Germany).
Gottsacker slopes contains sodium pyruvate for isolation of
Mycobacterium bovis. Cultures were incubated at 37 C for up to
8 weeks. Conﬁrmation of MTB was done based on presumptive
phenotypic appearance of colonies and by line probe assay
(GenoType®MTBC; Hain Life science, Nehren, Germany).
2.4. Phenotypic drug susceptibility testing by BacT/
Alert® 3D system
M. tuberculosis isolates were tested for their resistance to
rifampicin (RMP), isoniazid (INH), streptomycin (SM), etham-
butol (EMB) and pyrazinamide (PZA) by a proportion method
using BacT/Alert® 3D system. Critical concentrations of 1 mg/
mL for RMP, INH, and SM; 2 mg/mL for EMB and 200 mg/mL
for PZA were respectively used [17,18]. The PZA bottles were
incubated in BacT/Alert® 3D automated system at 37 C, as
mycobacteria designed blood culture bottles to inactivate the
delta-algorithm of the system for growth detection in order to
avoid false drug-resistant results. Growth was monitored daily,
and an isolate was considered resistant to a drug under test when
the drug-containing bottle had a time to detection (TTD) that
was less or equal to the TTD of the 1% control bottle.
Deﬁnitions: Any resistance was deﬁned as resistance to one
or more ﬁrst-line anti-TB drugs. Mono-resistance was deﬁned as
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SM, EMB and PZA). MDR-TB was deﬁned as M. tuberculosis
isolate that is resistant to at least INH and RMP. Resistance
among new cases was deﬁned as patient with TB resistant to one
or more anti-TB drugs, but who had never been previously
treated for TB. Resistance among previously treated cases, was
deﬁned as patients diagnosed with TB who started anti-TB
treatment and subsequently acquired resistance to one or more
of the drugs used during treatment [19].2.5. M. tuberculosis genomic DNA extraction
Mycobacterial cells from positive BacT/Alert® bottles and
from LJ slopes showing visible positive growth were used for
DNA extraction. Brieﬂy, bacterial DNA was extracted from
heat-inactivated AFB isolates. A loopful of colony material was
placed into a labelled screw caped eppendorf tube containing
500 mL sterile distilled water or by taking 500 mL from a positive
BacT/Alert® bottles. Each specimen was incubated on a heat
block at 95 C for 20 min to inactivate the bacteria. Then
centrifuged at 14 000 g for 15 min, the supernatant was dis-
carded using pasture pipette, followed by addition of 200 mL
distilled water to resuspend the pellets. This was followed by
maximum vortexing for 10 s to homogenize the sediments. The
tubes were incubated in an ultrasonic water bath at 95 C for
15 min in order to rupture the inactivated mycobacterial cells to
release the genomic DNA. The tubes were ﬁnally centrifuged at
14 000 g for 15 min. The supernatant was immediately used for
PCR or transferred to a new sterile eppendorf for longer storage
at −20 C until used.Figure 1. Flow diagram showing patients enrolled for drug susceptibility
test (DST) of ﬁrst-line anti-TB drugs in Tanga, Tanzania; November 2012–
January 2013.2.6. Genotypic drug susceptibility testing
Genotypic drug susceptibility testing for RMP and INH was
performed using Genotype®MTBDRplus assay (Hain Life Sci-
ence GmbH, Nehren, Germany). Genotypic detection of resis-
tance to EMB was done by using Genotype®MTBDRsl assay
(Hain Life Science GmbH, Nehren, Germany). PCR ampliﬁca-
tion, strip hybridization and interpretation of proﬁles were done
by following manufacturer's instructions.
2.7. Data management and analysis
Data were ﬁrst entered and cleared by using Ms Excel, then
analysed using SPSS version 20 (SPSS Inc, Chicago, IL, USA).
Unadjusted bivariate logistic regression analysis was performed
to determine the risk factors for drug-resistant TB and the
strength of the association was determined by odds ratio (OR)
with 95% conﬁdence interval (95% CI) and P-value of <0.05
was considered statistically signiﬁcant.
The study was approved by the Ethical Review Committee of
the National Institute for Medical Research, Dar es salaama,
Tanzania. All patients gave verbal informed consent to partici-
pate in the study.
3. Results
3.1. M. tuberculosis culture results
From among 372 TB suspect patients enrolled in the study
312 (83.9%) were new and 60 (16.1%) were previously treatedcases. Of the 312 new cases enrolled, 182 (58.3%) were culture
negative, 33 (10.6%) contaminated and 97 (31.1%) had culture
positive results. Of the 97 cases with culture positive results, 27
(27.8%) were excluded from the study because they were
NTMs; only 70 (72.2%) cases from this category were eligible
for DST. Of the 60 previously treated cases, 42 (70%) were
culture negative, 5 (8.3%) were contaminated and 13 (21.7%)
were culture positive. Four (30.8%) cases were excluded from
the test because they were NTMs and nine (69.2%) were eligible
for the DST. Overall, 79 (21.2%) out of 372 patients with
positive M. tuberculosis isolates were eligible for phenotypic
and genotypic DST as illustrated in Figure 1.
3.2. Demographic characteristics of the patients
The demographic characteristics of 79 (21.2%) patients who
had positive MTB isolates were analysed for DST of the ﬁrst
line anti-TB drugs in this study. 70 (88.6%) were new and 9
(11.6%) were previously treated (repeat) cases. These included
55 (69.6%) males and 24 (30.4%) females with the mean age of
(35.8 ± 12.6) years. Other demographic characteristics of the
patients are shown in Table 1.
3.3. Drug resistance prevalence by phenotypic DST
Of the 79 patients with DST data, the overall proportion of
any drug resistance was 12.7% (n = 10/79) and that of MDR-
TB was 6.3% (n = 5/79). The proportion of any drug resistant
anti-TB drug among new cases was 11.4% (n = 8/70) and the
proportion of MDR-TB in this category was 4.3% (n = 3/70);
whereas resistance to any drug and that of MDR-TB among
previously treated cases were respectively 22.2% (n = 2/9).
The proportions of any drug resistance and MDR-TB among
HIV sero-positive patients were 30.8% (n = 4/13) and 23.1%
(n = 3/13) respectively, while among the sero-negative group
Table 1
Characteristics of patients enrolled for anti-TB drug susceptibility test in
Tanga, Tanzania, November 2012–January 2013.
Characteristic New
(n = 70) (%)
Repeat
(n = 9) (%)
Sex Male 47 (67.1) 8 (88.9)
Female 23 (32.9) 1 (11.1)
Age <35 years 37 (52.9) 4 (44.4)
35 years 33 (47.1) 5 (55.6)
Residence Rural 36 (51.4) 3 (33.3)
Urban 34 (48.6) 6 (66.7)
Site Makorora HC 5 (7.1) 0
Ngamian HC 20 (28.6) 6 (66.7)
Bombo RH 14 (20.0) 0
MDHH 31 (44.3) 3 (33.3)
Disease type Smear+ Culture+ 48 (68.6) 6 (66.7)
Smear− Culture+ 22 (31.4) 3 (33.3)
HIV status Positive 11 (15.7) 2 (22.2)
Negative 59 (84.3) 7 (77.8)
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(Table 2).
3.4. Analysis of risk factors associated with any drug
resistance and MDR-TB
Using unadjusted logistic regression model risk factors
associated with any drug resistance and MDR-TB were deter-
mined. The patients were grouped into seven groups with the
following characteristics in each group: Sex: males 55 (69.6%)
cases, females 24 (30.4%) cases; age <35years: 41 (51.9%)
cases; age 35 years: 38 (48.1%). With respect to residence, 40
(50.6%) were from urban and 39 (49.4%) from rural. Seventy
(88.6%) were new and 9 (11.4%) were previously treated cases.
With respect to HIV status 13 (16.5%) were HIV sero-positive,
and 66 (83.5%) were sero-negative. With respect to disease type
55 (69.4%) were both smear and culture positive, while 24
(30.4%) were smear negative but culture positive. RegardingTable 2
Unadjusted bivariate logistic regression analysis of risk factors associated w
Variable n Susceptible
n (%)
Any DR n (%) OR
Sex Male 55 48 (87.3) 7 (12.7) 0.44 (0
Female 24 21 (87.5) 3 (12.5) Ref
Age <35 years 41 36 (87.8) 5 (12.2) 0.98 (0
35 years 38 33 (86.8) 5 (13.2) Ref
Residence Rural 39 35 (89.7) 4 (10.3) 0.29 (0
Urban 40 34 (85.0) 6 (15.0) Ref
Treatment
history
New case 70 62 (88.6) 8 (11.4) 0.38 (0
Previously treated 9 7 (77.8) 2 (22.2) Ref
Site Makorora HC 5 5 (100.0) 0 –
Ngamian HC 26 22 (86.4) 4 (15.4) 0.25 (0
Bombo RH 14 13 (92.9) 1 (7.1) 0.15 (0
MDHH 34 29 (85.3) 5 (14.7) Ref
Disease
Type
Smear+ Culture+ 54 46 (85.2) 8 (14.8) 1.61 (0
Smear− Culture+ 25 23 (92.0) 2 (8.0) Ref
HIV status Sero-positive 13 9 (69.2) 4 (30.8) 0.42 (0
Sero-negative 66 60 (90.9) 6 (9.1)
Total 79 10 (12.7)
DST, drug susceptibility testing; DR, drug resistance; MDR-TB, multidrug-disease type, we interestingly detected 8.0% (n = 2/25) cases
with any drug resistance and 4.0% (n = 1/25) case of MDR-TB
among smear negative but culture positive patients. There was
no signiﬁcance difference among all variables analysed with
development of any drug resistance or with MDR-TB in this
population as shown in Table 2.3.5. Resistance patterns of M. tuberculosis isolates
Table 3 shows different resistance patterns among new and
previously treated (repeat) cases. Overall 87.3% of all cases
were susceptible to all ﬁrst line anti-TB drugs. Among the newly
registered patients, any resistance to INH and RMP was each
found in four (5.7%) isolates, resistance to SM in three (4.3%),
any resistance to EMB and PZA was each found in 2 (2.9%)
isolates and 4 (5.7%) isolates showed MDR-TB. Among the
previously treated cases, any resistance to INH, SM and EMB
were each found in 2 (22.2%) cases, any resistance to RMP and
PZA was each found in one (11.1%) case and MDR-TB was
found in one (11.1%) case, which was resistant to all ﬁrst line
ant-TB drugs. The overall prevalence of any resistance and
MDR-TB when new and previously treated cases were com-
bined was 12.7% and 6.3% respectively. Mono-resistance was
only observed for SM and PZA in 1.4% each, all being from
newly registered cases as shown in Table 3.
3.6. Comparison between phenotypic and genotypic
drug susceptibility testing
Congruent results between phenotypic DST performed by
BacT/Alert® 3D system and Genotype®MTBDRplus assay were
obtained in 72 (91.1%) of the 79 subjects. Of 72 isolates iden-
tiﬁed as being susceptible to both INH and RMP by BacT/Alert®
3D, 66 (91.7%) cases were congruent by Genotype®MTBDR-
plus. 3 (4.2%) isolates were detected as MDR-TB by both
methods and all with mutations in the rpoß gene and katG gene
as shown by Genotype®MTBDRplus. Two (40.0%) isolates
detected by BacT/Alert® 3D as MDR-TB, were detected by theith any drug resistance and MDR-TB.
, 95% CI P value MDR-TB n (%) OR, 95% CI P value
.87–2.22) 0.32 3 (5.5) 0.37 (0.1–2.7) 0.33
2 (8.3) Ref
.21–4.57) 0.97 3 (7.3) 1.66 (0.2–4.9) 0.61
2 (5.3) Ref
.012–7.36) 0.46 3 (7.7) 0.34 (0.004–28.73) 0.64
2 (5.0) Ref
.05–2.97) 0.36 3 (4.3) 0.44 (0.03–7.42) 0.57
2 (22.2) Ref
0 – –
.01–6.62) 0.41 1 (3.9) 0.9 (0.001–9.11) 0.31
.03–7.96) 0.35 0 (0) 0.19 (0.001–29.1) 0.52
4 (11.8) Ref
.27–9.53) 0.60 4 (7.4) 1.94 (0.18–21.03) 0.59
1 (4.0) Ref
.08–2.35) 0.33 3 (23.1) 0.21 (0.03–1.43) 0.11
2 (3.0) Ref
5 (6.3)
resistant tuberculosis; OR, odds ratios.
Table 3
Drug resistance patterns to ﬁrst line anti-TB drugs in Tanga, Tanzania
(new vs repeat cases).
Resistance pattern New
n (%)
Repeat
n (%)
Total
n (%)
Total patients n = 70 n = 9 n = 79
Susceptible to all drugs 62 (88.6) 7 (77.8) 69 (87.3)
¥Any resistance 8 (11.4) 2 (22.2) 10 (12.7)
Any resistance to;
INH 4 (5.7) 2 (22.2) 6 (7.6)
RMP 4 (5.7) 1 (11.1) 5 (6.3)
SM 3 (4.3) 2 (22.2) 5 (6.3)
EMB 2 (2.9) 2 (22.2) 4 (5.1)
PZA 2 (2.9) 1 (11.1) 3 (3.8)
All INH + RMP
resistant (MDR-TB)
4 (5.7) 1 (11.1) 5 (6.3)
INH + RMP (only) 1 (1.4) 0 1 (1.3)
INH + RMP + SM 2 (2.8) 0 2 (2.5)
INH + RMP + EMB 1 (1.4) 0 1 (1.3)
INH + RMP + PZA 0 0 0
INH + RMP + SM +
EMB + PZA
0 1 (11.1) 1 (1.3)
INH + Other resistance 0 2 (22.2) 2 (2.5)
INH + SM 0 1 (11.1) 1 (1.3)
INH + EMB 0 0 0
INH + PZA 0 0 0
INH + SM + EMB 0 1 (11.1) 0
INH + SM + EMB + PZA 0 0 1 (1.3)
RMP + Other resistance 0 1 (11.1) 1 (1.3)
RMP + SM 0 0 0
RMP + EMB 0 0 0
RMP + PZA 0 0 0
RMP + SM + EMB + PZA 0 1 (11.1) 1 (1.3)
*Mono-resistance to 2 (2.9) 0 2 (2.5)
INH 0 0 0
RMP 0 0 0
SM 1 (1.4) 0 1 (1.3)
EMB 0 0 0
PZA 1 (1.4) 0 1 (1.3)
INH, isoniazid; RMP, rifampicin; SM, streptomycin; EMB, ethambutol;
PZA, pyrazinamide; ¥Any resistance: Resistance to any of the ﬁrst-line
anti-TB either in combination or as single; *Mono-resistance: Resistance
to only one anti-TB drug.
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Overall Genotype®MTBDRplus detected 3 (3.8%) isolates as
RMP mono-resistant, whereas no isolate could be detected as
RMP mono-resistant by the BacT/Alert® 3D. On the other hand,
2 (2.5%) isolates were detected by either methods as INH mono-
resistant; with one (1.4%) having mutation in katG gene and one
missed by the genotypic method as depicted in Table 4.Table 4
Comparison of resistance patterns of 79 M. tuberculosis isolates to INH and
Genotypic resistance pattern
INHs/RMPs n (%) INHr/RMPs n
INHwt/RMPwt 65 (91.7) 1 (50.0)
INHmut/RMPmut 3 (4.2) 0
INHmut/RMPwt 1 (1.4) 1 (50.0)
INHwt/RMPmut 3 (4.2) 0
Total 72 (91.1) 2 (2.5)
INHs, isoniazid sensitive; INHr, isoniazid resistance; RMPs, rifampicin sensit
mutation; INHmut, isoniazid with mutation band detected; RMPwt, rifampicin
detected; MDR-TB, multidrug-resistant tuberculosis.4. Discussion
Our key ﬁndings show that the prevalence of resistance to
any anti-TB drug among new patients was 11.4% and that of
MDR-TB was 4.3%, whereas among previously treated patients
the resistance to any anti-TB drug and MDR-TB were respec-
tively 22.2%. The overall resistance to any anti-TB drugs and
MDR-TB when newly and previously treated cases were com-
bined was 12.7% and 6.3% respectively. The overall prevalence
to any resistance of 7.6% for INH; 6.3% for RMP and SM; 5.1%
for EMB and 3.8% for PZA were high. The levels reported in
our study are higher than those reported during the last national
DST survey [11]. These proportions are alarming, hence calling
for immediate intervention to reverse the trend, as it raises
concern on the increased transmission of drug resistant MTB
in the settings.
High proportion of resistance to any drug (22.2%) and MDR-
TB among previously treated patients, also rises concerns on
continual reliance on home-based supervision of TB treatment as
previously advocated [20]; as patient adherence to treatment may
be difﬁcult to monitor, since the supervision of patients at home
is made by non-medical professionals. Moreover, the existence
of other resistance patterns with INH and or RMP among pre-
viously treated patients further reafﬁrms the concern over the
home-based supervision of TB patients. Although no association
to any anti-TB drug and or MDR-TB was found between newly
and previously treated cases, our ﬁndings show that 22.2%
(n = 2/9) of the previously treated cases were more likely to
develop resistance to ﬁrst-line anti-TB drugs. Lack of associa-
tion between history of treatment with DR-TB and MDR-TB
observed could be due to low number of previously treated
patients enrolled during the study.
Observed mono-resistance to SM and PZA in 2.9% among
new patients is plausibly an indication of growing use of these
antibiotics in the treatment of other bacterial infections in the
community. Generally, our ﬁndings are well in agreement with
those of the nation-wide survey, which showed the prevalence of
any resistance among new and previously treated patients in the
range of 8.3% and 20% respectively [11]. The observed
resistance to PZA in this study is, to the best of our
understanding reported for the ﬁrst time in Tanzania. The
standard practice for drug resistance surveys has been to test
for four ﬁrst-line drugs (INH, RMP, EMB and SM); and for
the purposes of surveys NTPs are required to perform, at min-
imum DST for INH and RMP on all cases included in the survey
[21]. From the ﬁndings of this study, it may be worth including
DST for PZA especially among HIV positive patients.RMP by phenotypic and genotypic method.
Phenotypic resistance pattern
(%) INHs/RMPr n (%) MDR-TB n (%) Total n (%)
0 2 (40.0) 68 (86.1)
0 3 (60.0) 6 (7.6)
0 0 2 (2.5)
0 0 3 (3.8)
0 5 (6.3) 79 (100)
ive; RMPr, rifampicin resistance; INHwt, isoniazid wild type gene without
wild type gene without mutation; RMPmut, rifampicin with mutation band
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4.0% among smear-negative but culture-positive patients in this
study need to be addressed with special concern, as this suggests
the inadequacy of peripheral microscopy performance. Several
studies have shown that peripheral smear microscopy in
Tanzania has frequently more problems in false-negative slides
than in false-positive [22].
Although several reports from other countries, have docu-
mented that HIV positivity is an important risk factor associated
with primary MDR-TB [23–26], and that HIV infection has been
associated with MDR-TB outbreaks in institutional settings,
such as hospitals and prisons [27,28]. Our ﬁndings showed lack of
association between anti-TB drug resistance in patients with or
without HIV and these results are in agreement with studies
conducted in Mwanza, Tanzania [14]. This lack of association
could be explained by the fact that majority of HIV infected
TB patients are likely to be smear negative and tend to have
lower rate of sputum smear positivity [29].
Of the 5 (6.3%) MDR isolates detected in our study, 2/5
isolates showed discordant results by BacT/Alert® 3D system
and Genotype®MTBDRplus.While BacT/Alert® 3D detected all
isolates as being INH resistant, the later detected one of the
isolate as INH mono-resistant and the other as INH susceptible.
Possible explanation of this disparity could be due to presence of
mutations outside the 81-bp “hot-spot” of the rpoB gene, though
this does occur less frequently [30,31]. Such mutations may occur
for example at codon 490 CAG to CAG [32], codon 534 (GGG to
GAG), codon 535 (CCC to CAC) [33] and at codon 572 (ATC to
TTC) [34]. Another possible explanation could be due to changes
occurring in genes whose products participate in antibiotic
permeation or metabolism [35]. Several studies have also
indicated presence of high discordance in RMP susceptibility
testing [36,37]. Since the Genotype®MTBDRplus assy we used
is not very robust; such methods like DNA sequencing may
be considered for isolates with discordant results.
Limitations: The small sample size may have limited the
generalization of the observed results in our study. High rates of
culture negative and contaminated specimens may be attributed
to such factors as: (i) inclusion of specimens with very low
bacilli load resulting to loss of viability during culture, (ii) un-
derstaffed and overburdened of the clinics with other non-TB
patients might have led to delayed sample processing, (iii)
frequent power interruption may have resulted into inappropriate
cold chain maintenance at the clinic level, (iv) some patients
failing to deliver early morning samples within the speciﬁed
period, due to among other factors long distance and costs of
travel to and from the clinics. Despite the limitations of the
study, it has provided important information regarding the
resistance proﬁles at the facility-base level where majority of the
patients may not have opportunity to be covered during the
national drug resistance surveys. High proportions of anti-TB
drug resistance among new and previously treated cases, gives
an insight of DR-TB situation at facility levels in the country.
Therefore, it provides for a better planning of the drug resistance
surveys including improving smear microscopy performance for
case detection and improvement of TB control programmes.
Frequent drug resistance survey need to be done in order to
monitor the situation of DR-TB in the country.
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